Spectrum Vascular Appoints New Executive Leadership Team
Spectrum Vascular, a fast-growing provider of vascular access and medication management products designed to reduce healthcare-associated infections (HAIs), has announced the appointment of two high-impact leaders to its executive team. Ken Miller has been named Chief Executive Officer (CEO), while Doug Shook will take on the role of Chief Commercial Officer (CCO). These pivotal appointments come on the heels of a significant strategic investment from private investment firm SK Capital Partners in March and mark a critical inflection point in the company’s journey toward becoming a market leader in infection prevention technologies.
With the addition of Miller and Shook, Spectrum Vascular is positioning itself to accelerate commercial execution, broaden its reach across acute and post-acute care settings, and deepen its impact on patient outcomes through advanced medical technologies focused on safety, efficiency, and infection reduction. The leadership moves are expected to strengthen Spectrum’s go-to-market capabilities while reinforcing its commitment to innovation and clinical value.
Strategic Momentum Following SK Capital Investment
The leadership appointments follow a strategic equity investment from SK Capital Partners, a private investment firm known for supporting companies in the healthcare, life sciences, and specialty materials sectors. The infusion of capital in late March 2025 was aimed at supporting Spectrum’s long-term growth strategy, including investment in research and development, commercial expansion, and talent acquisition.
“Spectrum Vascular is uniquely positioned at the intersection of patient safety and healthcare efficiency,” said Jon Borell, Managing Director at SK Capital. “Ken and Doug are proven leaders who share our values and vision. Their appointments represent a major step forward as we build on the momentum established by our recent investment.”
Borell emphasized the importance of leadership alignment as Spectrum embarks on its next phase of development. “The Spectrum Vascular Board of Directors, as well as the SK Capital and Event Capital Strategies teams, are thrilled to partner with Ken and Doug. Together, we are committed to scaling Spectrum’s solutions across key markets, expanding access to care, and driving sustainable improvements in patient outcomes.”
Ken Miller Brings Deep Operating Expertise as CEO
Ken Miller assumes the role of CEO with more than 35 years of experience in the medical device and healthcare technology sectors. Throughout his career, Miller has established himself as a transformational leader known for delivering operational excellence, commercial innovation, and strategic growth across both emerging and established companies.
Most recently, Miller served as Chief Commercial Officer at KORU Medical Systems, a manufacturer of subcutaneous infusion technologies. During his tenure, he was instrumental in realigning the commercial organization, launching new products, and building scalable infrastructure to support long-term growth. Prior to KORU, he held key executive leadership roles at several prominent healthcare companies, including Nasco Healthcare, Becton Dickinson (BD), and Novo Nordisk. His track record includes leading high-performing teams, accelerating revenue growth, and expanding market presence in highly competitive segments of the healthcare industry.
“I am honored to join Spectrum Vascular at such a pivotal time in the company’s evolution,” said Miller. “Spectrum’s mission to improve patient care through infection prevention aligns perfectly with my professional values and personal passion Spectrum Vascular for healthcare innovation. The company has already made impressive strides with its differentiated portfolio and strong clinical focus. With the backing of SK Capital and a talented team in place, I’m confident we can take Spectrum to the next level.”
Miller’s appointment is expected to bring a disciplined operational approach to Spectrum’s growth initiatives, including enhanced clinical engagement, expanded commercial capabilities, and strategic partnerships that further the company’s reach in acute, ambulatory, and alternate site care settings.
Doug Shook Appointed Chief Commercial Officer, Brings Over 20 Years of Market Strategy Expertise
Joining Miller at the helm is Doug Shook, who brings over two decades of commercial leadership experience in the medical technology space, particularly within the vascular access sector. As Spectrum’s new Chief Commercial Officer, Shook will be responsible for driving market strategy, accelerating customer adoption, and deepening relationships with healthcare systems, clinicians, and supply chain partners.
Prior to joining Spectrum, Shook served as the Global Business Unit Leader for Vascular Access at ICU Medical. In this role, he led commercial strategy and operations across a wide portfolio of vascular access products, including central venous catheters, midlines, and peripheral intravenous catheters. His leadership helped drive product innovation, margin expansion, and strategic account growth across domestic and international markets.
Earlier in his career, Shook held commercial leadership roles at Smiths Medical and Access Scientific, both of which are recognized for developing advanced vascular access technologies designed to reduce catheter-related bloodstream infections (CRBSIs) and improve insertion outcomes in both hospital and outpatient settings.
“I’m excited to join Spectrum at a time of strong momentum and opportunity,” said Shook. “What attracted me to this organization is its deep commitment to infection prevention and clinical excellence. With a differentiated portfolio of products and a strong focus on outcomes, we’re in a prime position to grow our market presence and support health systems in achieving their safety and quality goals.”
A Shared Vision for Infection Prevention and Better Outcomes
Spectrum Vascular’s portfolio includes a range of products designed to reduce the risk of HAIs through improved vascular access, securement, and medication delivery. As hospital-acquired infections continue to pose a serious burden on healthcare systems—impacting patient safety, driving up costs, and triggering reimbursement penalties—Spectrum’s mission has taken on renewed urgency.
According to the Centers for Disease Control and Prevention (CDC), approximately one in 31 hospitalized patients will experience at least one healthcare-associated infection on any given day. Spectrum aims to address this issue head-on by delivering clinically validated technologies that reduce complications such as bloodstream infections, phlebitis, and catheter dislodgement.
The company’s product lines are used by a wide range of healthcare providers across acute and post-acute settings, and include needleless connectors, catheter securement devices, and other access-related innovations designed with clinician input and patient safety at the forefront.
With Miller and Shook at the leadership helm, Spectrum plans to expand its product pipeline, strengthen its customer relationships, and explore new opportunities for strategic growth—whether through organic innovation, partnerships, or potential acquisitions.
Scaling with Purpose
The appointments of Miller and Shook represent more than just leadership changes—they signal a broader transformation in how Spectrum plans to operate, grow, and lead in its category. With seasoned executives who understand both the clinical and commercial dimensions of the business, the company is poised to scale its reach while staying true to its core mission.
“Spectrum is entering a new era of purpose-driven growth,” Miller concluded. “By working closely with healthcare providers, listening to their needs, and delivering reliable, evidence-based solutions, we will continue to raise the standard for vascular access and infection prevention across the continuum of care.”
As Spectrum Vascular charts its path forward under this new leadership team, the company stands ready to meet the challenges and opportunities of a dynamic healthcare landscape—driven by a shared commitment to better outcomes, safer care, and long-term value for patients and providers alike.
